TargoPep uses its next-generation platform to design, research and refine targeted neurological delivery solutions for oligonucleotide therapeutics.
Our biological and chemical expertise, patented chemical solutions and innovative design principles enable our bespoke, peptide-based delivery systems to provide tailored drug delivery. Our technology overcomes barriers often associated with the clinical application of oligonucleotide-based therapeutics.
Current delivery solutions rely on non-ideal and clinically limiting methods, which are expensive, time-consuming to adapt and are holding back discovery and the development of treatment options.
Our modular, dynamic and versatile approach enables TargoPep to address these neuro-delivery needs and expand the possibilities for oligonucleotide cures into the clinic.
Current delivery solutions rely on non-ideal and clinically limiting methods, which are expensive, time-consuming to adapt and are holding back discovery and the development of treatment options.
Our modular, dynamic and versatile approach enables TargoPep to address these neuro-delivery needs and expand the possibilities for oligonucleotide cures into the clinic.
Our development pipeline is focused on providing bespoke and targeted delivery solutions to treat Neurofibromatosis type 1 (NF1) and Parkinson’s disease.
Currently under-served by treatment options, TargoPep will deliver therapies to create a real-world difference to people’s lives.
Augmenting your therapeutic pipeline with TargoPep’s unique delivery technologies can accelerate those therapies into the clinic.
TargoPep’s modularity and diversity of potential solutions provides multiple options for partners to explore.
TargoPep Ltd., Suite 2, Orchard Brae House, 30 Queensferry Road, Edinburgh EH4 2HS, United Kingdom
info@targopep.com
TargoPep Ltd. is a company registered in Scotland SC715354 | All content © 2024 TargoPep Ltd.